Skip to content

Study · Not a test of the peptide alone · 2004

3 results

Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.

Micic D, Kendereski A, Sumarac-Dumanovic M, Cvijovic G, Popovic V, Dieguez C, Casanueva F

Diabetes research and clinical practice1 Jan 2004Cited by 5 (Europe PMC)

PMID14693411 (opens in a new tab)DOI10.1016/j.diabres.2003.08.012 (opens in a new tab)PepBankPUB-14693411
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In men with type 2 diabetes, basal GH did not differ between the hyperglycemic and euglycemic clamps.

    In plain wordsIn men with type 2 diabetes, starting growth hormone levels were similar during high and normal blood glucose.

    Peptide
    GHRP-6
    Outcome
    No significant changeBasal GH, hyperglycemic versus euglycemic clamp
    Study

    n = 12

    Comparator
    Euglycemic clamp
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Basal GH
    2.9 mU/l
    hyperglycemic clamp
    Basal GH
    1.48 mU/l
    euglycemic clamp

    Source sentences

    Summary
    There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9+/-0.99 mU/l versus 1.48+/-0.44 mU/l; P>0.05).
    1 context sentence
    Summary · context
    GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In men with type 2 diabetes, the peak GH response to combined GHRH and GHRP‑6 was lower during a hyperglycemic clamp than during a euglycemic clamp.

    In plain wordsIn men with type 2 diabetes, the growth hormone peak after a GHRH plus GHRP‑6 injection was lower when blood glucose was high.

    Peptide
    GHRP-6
    Outcome
    DecreasePeak GH response to GHRH+GHRP-6
    Study

    n = 12

    Comparator
    Euglycemic clamp
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak GH
    112.45 mU/l
    hyperglycemic clamp
    Peak GH
    151.06 mU/l
    euglycemic clamp

    Source sentences

    Summary
    Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45+/-14.45 mU/l versus 151.06+/-16.87 mU/l; P<0.05).
    1 context sentence
    Summary · context
    GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In men with type 2 diabetes, the GH area under the curve after combined GHRH and GHRP‑6 was lower during a hyperglycemic clamp than during a euglycemic clamp.

    In plain wordsIn men with type 2 diabetes, total growth hormone release after GHRH plus GHRP‑6 was lower when blood glucose was high.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH area under the curve after GHRH+GHRP-6
    Study

    n = 12

    Comparator
    Euglycemic clamp
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC
    6974.49 mU/l/min
    hyperglycemic clamp
    GH AUC
    9560.75 mU/l/min
    euglycemic clamp

    Source sentences

    Summary
    Area under the GH curve was lower in the hyperglycemic than in the euglycemic clamp (6974.49+/-1001.95 mU/l/min versus 9560.75+/-1140.65 mU/l/min; P<0.05).
    1 context sentence
    Summary · context
    GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.